Clinical trials: Impaired Renal Function
Chronic Kidney Disease
The BASE Study: Bicarbonate Administration to Stabilize Estimated Glomerular Filtration Rate (eGFR)
The two doses of sodium bicarbonate being tested are 0.5 and 0.8 mEq/kg-lean body weight (LBW) per day. Sodium bicarbonate, also known as baking soda, may help prevent kidney failure in people with chronic kidney disease.
- Trial name
- BASE (NCT02521181)
- Testing
- Lower Dose Sodium Bicarbonate, Higher Dose Sodium Bicarbonate
- Where
- 7 sites in United States
- Volunteers
- 194 people
- Sponsor
- Jennifer Gassman, PhD
Chronic Kidney Disease, Hyperparathyroidism, Secondary
Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002
This extension study of subjects previously enrolled in studies CTAP101-CL-3001 or CTAP101-CL-3002 allows long term evaluation of the safety and efficacy of CTAP101 Capsules in reducing elevated intact parathyroid hormone (iPTH)…
- Conditions
- Chronic Kidney Disease, Hyperparathyroidism, Secondary, Vitamin D Deficiency
- Trial name
- NCT02282813
- Testing
- CTAP101 Capsules, Calcitriol, Doxercalciferol
- Volunteers
- 298 people
- Sponsor
- OPKO Health, Inc.
Chronic Kidney Disease
A Study to Assess the Relative Bioavailability of 3 Different Formulations Under Fasted and Fed Condition
This study is intended to assess the relative bioavailability between the (extended-release) ER8 capsule formulation (the formulation that is currently used for verinurad development) given under fasted conditions and 2 new…
- Trial name
- NCT04024501
- Testing
- Verinurad ER8 capsule formulation (fasted), Verinurad A-capsule formulation (fasted), Verinurad A-capsule formulation (fed)
- Where
- Germany
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
End Stage Renal Disease
Treatment Modification to Reduce Symptom Burden in Hemodialysis
Many patients on hemodialysis experience high rates of symptom burden, such as pain, depression, anxiety and difficulty breathing.
- Trial name
- NCT01775800
- Testing
- Treatment modification
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- The Rogosin Institute
Kidney Diseases, Kidney Injury
Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring
The goal of this clinical trial was to compare transdermal glomerular filtration rate (tGFR) to plasma-derived indexed GFR (nGFR) using MB-102 (relmapirazin) as the fluorescent compound.
- Conditions
- Kidney Diseases, Kidney Injury, Kidney Failure
- Trial name
- NCT05777174
- Testing
- MB-102, MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)
- Where
- 5 sites in United States
- Volunteers
- 149 people, healthy volunteers welcome
- Sponsor
- MediBeacon
ESRD
Interventions Made to Preserve Cognitive Function
This is a randomized, controlled trial to slow cognitive decline in adults undergoing hemodialysis (HD). The investigators will test three interventions cognitive training (CT), exercise training (ET), and combined cognitive and…
- Trial name
- IMPCT (NCT03616535)
- Testing
- Cognitive training, Exercise training, Combined cognitive and exercise training
- Where
- 2 sites in United States
- Volunteers
- 130 people
- Sponsor
- Johns Hopkins University
End-stage Renal Disease
Vitamin D and Arteriovenous Fistulae
Patients requiring hemodialysis following kidney failure need a form of dialysis vascular access in order to undergo the dialysis procedure. Dialysis vascular access dysfunction is an enormous clinical problem.
- Trial name
- NCT00912782
- Testing
- Vitamin D3
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Emory University
Hyperkalemia, Resistant Hypertension
Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease
The purpose of this study is to determine if patiromer treatment in chronic kidney disease (CKD) subjects receiving spironolactone for the treatment of resistant hypertension will result in more persistent use of spironolactone…
- Trial name
- AMBER (NCT03071263)
- Testing
- Patiromer, Spironolactone
- Where
- 40 sites in United States, Bulgaria and 7 more
- Volunteers
- 295 people
- Sponsor
- Relypsa, Inc.
Congestive Heart Failure, Cardiac Transplantation
Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC
The purposes of this study in United Network for Organ Sharing (UNOS) Status 1B (or country equivalent) cardiac transplant candidates are to assess the safety and efficacy of Natrecor (nesiritide).
- Conditions
- Congestive Heart Failure, Cardiac Transplantation, Renal Insufficiency, Renal Failure
- Trial name
- NCT00338455
- Testing
- Natrecor (nesiritide)+Standard Care+dobutamine or milrinone
- Where
- 14 sites in United States
- Volunteers
- 16 people
- Sponsor
- Scios, Inc.
Anemia, Chronic Renal Failure
Safety & Efficacy of Peginesatide for Treatment of Anemia in Participants on Dialysis Not Receiving an ESA
The purpose of this study is to evaluate the safety and efficacy of peginesatide for the treatment of anemia in participants with chronic kidney disease who are on dialysis and are not taking any treatment to increase their red…
- Conditions
- Anemia, Chronic Renal Failure, Chronic Kidney Disease
- Trial name
- NCT00680043
- Testing
- peginesatide, Epoetin Alfa
- Where
- 11 sites in Russia
- Volunteers
- 114 people
- Sponsor
- Affymax
Acute Heart Failure (AHF)
Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) Patients
This was a multinational, multicenter, randomized, open-label study to confirm and expand the efficacy, safety and tolerability evidence of 48 hours intravenous infusion of serelaxin (30 micrograms/kg/day) when added to Standard…
- Trial name
- RELAX-AHF-EU (NCT02064868)
- Testing
- Serelaxin, Standard of Care
- Where
- 357 sites in Austria, Belgium and 23 more
- Volunteers
- 2,666 people
- Sponsor
- Novartis Pharmaceuticals
End-stage Kidney Disease, Kidney Disease, Chronic
Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD
The purpose of this study is to find out if empagliflozin, a new diabetic medication that has been shown to be very effective in lowering the risk of heart failure, is safe and tolerated in dialysis patients.
- Conditions
- End-stage Kidney Disease, Kidney Disease, Chronic, Dialysis, Diabetic
- Trial name
- NCT05614115
- Testing
- Empagliflozin
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- University of Utah
Chronic Kidney Disease, Cardiovascular Disease
Management of Cardiovascular Disease in Kidney Disease (MaCK) Study
Cardiovascular disease (CVD) is the largest concerns for patients with Chronic kidney disease (CKD). At present time the investigators do not have proven effective strategies to reduce high CVD related deaths in CKD.
- Conditions
- Chronic Kidney Disease, Cardiovascular Disease, Inflammation, Atherosclerosis
- Trial name
- MaCK (NCT03636152)
- Testing
- MRI carotid, APWV, Hydroxychloroquine
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- VA Office of Research and Development
Chronic Kidney Disease (CKD)
A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis
A phase 3b study for subjects receiving Epogen to compare a dosing algorithm between Hospira Epoetin and Standard of Care Epogen.
- Trial name
- NCT02504294
- Testing
- Epoetin Hospira Arm, Standard of Care Arm, IV Iron
- Where
- 45 sites in United States, Puerto Rico
- Volunteers
- 432 people
- Sponsor
- Pfizer
Hypertension, Chronic Kidney Disease
Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age
The purpose of this study is to assess the long-term safety and tolerability profile of valsartan and valsartan-based treatments in children with hypertension, with or without chronic kidney disease.
- Trial name
- NCT01365481
- Testing
- Valsartan, amlodipine, Hydrochlorothiazide
- Where
- 28 sites in Colombia, Finland and 8 more
- Volunteers
- 150 people
- Sponsor
- Novartis Pharmaceuticals
Children, Obstructive Uropathy
Ureteral Stents Versus Percutaneous Nephrostomy for Initial Urinary Drainage
To compare percutaneous nephrostomy (PCN) versus double J stent (JJ) as an initial urinary drainage in children
- Conditions
- Children, Obstructive Uropathy, Acute Renal Failure, Ureteric Stones
- Trial name
- NCT02055430
- Testing
- percutaneous nephrostomy insertion, bilateral double J ureteric stent, Definitive stone management
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Cairo University
Diabetic Nephropathies
A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy
PF-00489791 is an inhibitor of phosphodiesterase type 5. Our hypothesis is that PF-00489791 will enhance the relaxation of blood vessels within the kidney and so reduce blood pressure, improving renal function.
- Trial name
- NCT01200394
- Testing
- PF-00489791
- Where
- 160 sites in United States, Australia and 13 more
- Volunteers
- 256 people
- Sponsor
- Pfizer
Renal Insufficiency
Assessing the Behavior of Met DR in Subjects With Kidney Dysfunction
This study evaluated how a single dose of delayed-release metformin (Met DR) behaves in subjects with normal kidney function, mild kidney dysfunction, moderate kidney dysfunction, or severe kidney dysfunction.
- Trial name
- NCT01658514
- Testing
- Met DR, Met XR
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Elcelyx Therapeutics, Inc.
Kidney Disease, Chronic
An Observational, Prospective, Safety Study of Mircera (Monopegylated Epoetin Beta) in Clinical Practice
This national study was a post-marketing surveillance study conducted in Korea from 29 August 2008 to 28 August 2012 to meet local regulatory requirements for Mircera (monopegylated-epoetin beta).
- Trial name
- NCT02263833
- Testing
- Mircera
- Where
- South Korea
- Volunteers
- 748 people
- Sponsor
- Hoffmann-La Roche
Renal Impairment
Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Normal Renal Function or With Severe Renal Impairment
This study will be conducted to assess the effect of severe renal impairment on the pharmacokinetics of lemborexant after a single-dose administration.
- Trial name
- NCT03443063
- Testing
- Lemborexant
- Where
- 2 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.